Research report on guidance for the multi-regional clinical trials

Xiao-fang ZHANG,Dan HUANG,Xiang-yu WANG,Gang CHEN,Chen YAO,Jing LI,Lin YUAN
2017-01-01
Abstract:With the globalization of drug development,more attention is paid on the multi-regional clinical trial (MRCT).The use of MRCT can expedite the simultaneous new drug development with more patient population sources,maintain a same level of scientific rigor in the trial design when the outcomes delivered to different regulatory agencies for evaluation and reduce unnecessary development cost.However,there are challenges and concerns with the use of MRCT to national drug regulation.Many countries,including China and the international organizations including ICH,have introduced their own provisions.This article compares MRCT regulatory requirements of US,EU and Japan,and introduces ICH related guidance and analyses of similarities and differences between ICH and China Food and Drug Administration guidance,with a view to inspire the supervision of the multi-regional clinical trial in China.
What problem does this paper attempt to address?